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ABSTRACT 
The high mortality of pancreatic cancer demands that new therapeutic avenues 
be developed. The orally available small molecule inhibitor AT13148 potently 
inhibits ROCK1 and ROCK2 kinases that regulate the actomyosin cytoskeleton. 
We previously reported that ROCK kinase expression increases with human and 
mouse pancreatic cancer progression and that conditional ROCK activation 
accelerates mortality in a genetically modified LSL-KrasG12D; LSL-p53R172H; 
Pdx1-Cre; (KPC) mouse pancreatic cancer model. In this study, we show that 
treatment of KPC mouse and human TKCC5 patient-derived pancreatic tumor 
cells with AT13148, as well as the ROCK selective inhibitors Y27632 and H1152, 
act comparably in blocking ROCK substrate phosphorylation. AT13148, Y27632, 
and H1152 induced morphological changes and reduced cellular contractile force 
generation, motility on pliable discontinuous substrates, and three-dimensional 
collagen matrix invasion. AT13148 treatment reduced subcutaneous tumor 
growth and blocked invasion of healthy pancreatic tissue by KPC tumor cells in 
vivo without affecting proliferation, suggesting a role for local tissue invasion as a 
contributor to primary tumor growth. These results suggest that AT13148 has 
anti-tumor properties that may be beneficial in combination therapies or in the 
adjuvant setting to reduce pancreatic cancer cell invasion and slow primary 
tumor growth. AT13148 might also have the additional benefit of enabling tumor 
resection by maintaining separation between tumor and healthy tissue 
boundaries. 
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INTRODUCTION 
Pancreatic cancer, and the predominant pancreatic ductal adenocarcinoma 
(PDAC) type in particular, is one of the deadliest of all major cancers with the 
lowest 5-year survival rate (1), and which has been projected to become the 
second leading cause of cancer deaths by 2030 in the United States (2). Despite 
intense efforts directed at improving patient outcomes, there has been little to no 
improvement in survival rates (3). Most patients are not treatable with surgical 
resection; chemotherapy is the most frequently used approach. One challenge 
for chemotherapy is that the mostly commonly mutated driver genes (KRAS, 
TP53, SMAD4 and CDKN2A (4,5)) are not targeted by current drugs. As a result, 
drugs that could be used in therapeutic combinations, in the adjuvant setting, or 
which might increase tumor resectability, could be beneficial and help to extend 
patient survival (6). 
The RhoA and RhoC regulated ROCK1 and ROCK2 serine/threonine 
kinases play central and critical roles in the regulation of actomyosin cytoskeleton 
organization and dynamics, acting largely through the phosphorylation of 
substrates including regulatory myosin light chain 2 (MLC2), myosin-binding 
subunit of the MLC phosphatase (MYPT1), and LIM kinases 1&2 (LIMK) (7-9). 
Numerous lines of evidence indicate that the ROCK kinases contribute to tumor 
cell invasion and metastasis, by increasing cytoskeleton contractility and cellular 
tension to affect properties including adhesion and migration (7). Conditional 
genetic deletion of both Rock1 and Rock2 in mouse cells also revealed essential 
roles in cell cycle progression, although this effect only appears to be manifested 
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following full or near complete loss of ROCK activity induced by gene deletion or 
high inhibitor concentrations (10). 
 The ROCK1 gene locus on human chromosome 18 is amplified in 15% of 
pancreatic tumors (11), an observation corroborated by a recent study in which 
ROCK1 gene amplification was observed in 12% of patient samples (12), and 
which was extended by the finding of concordancy between copy number and 
gene expression changes (4). We reported that there were significantly increased 
levels of ROCK1 and ROCK2 protein in human and mouse pancreatic tumors 
compared to healthy tissue, which were observed to increase in parallel with 
tumor progression (13). The observations of elevated ROCK1 protein in human 
pancreatic tumor tissues were also recently corroborated (12). Furthermore, 
siRNA-mediated knockdown of ROCK1/2 expression inhibited the proliferation 
and migration of pancreatic cancer cell lines in vitro (12). Importantly, elevated 
ROCK1 and/or ROCK2 expression was associated with reduced survival in 
human pancreatic patients, while conditional activation of ROCK2 in the 
genetically modified LSL-KrasG12D; LSL-p53R172H; Pdx1-Cre; (KPC) mouse 
pancreatic cancer model (14-16) also resulted in accelerated mortality (13). 
Conversely, treatment of KPC mice, or mice with orthotopically grown tumors of 
human TKCC5 patient-derived xenograft (PDX)-derived pancreatic cancer cells 
(17) with the selective ROCK inhibitor fasudil extended survival (13), consistent 
with ROCK inhibition having the potential to provide clinical benefit for pancreatic 
cancer patients. The physically stiff collagen-rich stroma associated with PDAC 
tumors was found to promote tumor growth via increased ROCK signaling (18), 
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while in PDAC cells oncogenic KRAS drives increased transcription of the RhoA-
activating ARHGEF2 guanine nucleotide exchange factor that promotes 
migration, invasion and colony formation (19). These findings are consistent with 
the additional scenario of a more general tumor promoting role for Rho-ROCK 
signaling in the absence of elevated ROCK1 or ROCK2 expression. 
If ROCK inhibition were to be considered for clinical development as a 
pancreatic cancer chemotherapeutic, there are several key requirements that 
should be met, including high potency and good pharmacokinetic properties. 
Although fasudil extended the survival of KPC pancreatic cancer mice (13) and 
mice with human TKCC5 PDAC cell orthotopic tumors (17), and the compound is 
clinically used in Japan in an acute manner to treat cerebral vasospasm with very 
good safety profiles (20), the frequent dosing with high compound concentrations 
that are necessary to achieve in vivo responses make fasudil a sub-optimal 
choice for extended chemotherapy. The pyrazole-based AT13148 ((1S)-2-amino-
1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)phenyl]ethanol) AGC kinase inhibitor 
was discovered in a fragment-based screen and further developed to optimize its 
potency and pharmacokinetic properties (21). Although originally intended to be 
an AKT inhibitor, subsequent biological experiments revealed that it was more 
potent as an inhibitor of ROCK1 and ROCK2 (21). Through comparisons with 
non-ROCK targeting AKT inhibitors, it was determined that an inhibitory effect on 
melanoma cell motility was due to on-target ROCK inhibition (22). In addition, 
AT13148 was shown to slow the subcutaneous tumor growth of BT474 breast, 
PC3 prostate and MES-SA uterine human cancer cell lines, revealing its in vivo 
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anti-tumor efficacy (21). Importantly, the therapeutic promise, satisfactory 
pharmacokinetic properties and selectivity profile of AT13148 contributed to its 
progression to phase 1 clinical trials (23). 
To model PDAC, we used tumor cells isolated from the KPC mouse PDAC 
model that expresses mutant KRAS and p53 (16), and the human patient derived 
xenograft (PDX)-derived cell line TKCC5 (17). We now show that AT13148 
phenocopied the selective ROCK inhibitors Y27632 and H1152 in blocking 
substrate phosphorylation in mouse and human PDAC cells. In addition, 
AT13148, Y27632 and H1152 induced morphological changes and reduced 
contractile force generation, cell motility on pliable discontinuous substrates and 
three-dimensional collagen matrix invasion. Treatment of mice with AT13148 or 
fasudil blocked invasion of healthy pancreatic tissue by KPC cells. Furthermore, 
AT13148 reduced KPC subcutaneous tumor growth, without affecting 
proliferation, suggesting a role for local tissue invasion as an important 
contributor to primary tumor growth. This study is the first to demonstrate that 
AT13148 inhibits ROCK activity in pancreatic cancer cells, and supports the 
conclusion that AT13148 has anti-tumor properties that make it a candidate for 
use in combination therapies, or in the adjuvant setting, to reduce tumor cell 
invasion and to slow primary tumor growth, which might have the additional 
benefit of enabling tumor resection by maintaining separation between tumor and 
healthy tissue boundaries.  
 
MATERIALS AND METHODS 
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Small molecule inhibitors 
AT13148 (Astex Pharmaceuticals), Y27632 (Tocris 1254), H1152 (Tocris 2414), 
fasudil (LC Laboratoris F-4660), GM6001 (Millipore 142880-36-2). 
 
Cell culture 
The KPC PDAC tumor cell line was established from a Pdx1-Cre; LSL-KrasG12D/+; 
LSL-Trp53R172H/+ mouse at the Cancer Research UK Beatson Institute as 
described in reference (16). KPC cells were cultured in high glucose DMEM 
(Gibco 21969-035) supplemented with 10% fetal bovine serum (FBS: Gibco), 2 
mmol/L L-glutamine (Gibco) and penicillin-streptomycin (Gibco). The TKCC5 
human pancreatic cancer cell line was established from patient-derived xenograft 
(PDX)-derived tumor cells at The Kinghorn Cancer Centre, Garvan Institute of 
Medical Research, and their culture conditions were described in reference (17). 
Given that these pancreatic cancer cell lines were created at the institutions 
where the experiments described in this study were performed, there were no 
previous references against which their identities could be authenticated, and no 
methods of authentication were used. Cells were cultured only for up to ~2 
months after recovery from vials of low passage number KPC or TKCC5 cells. All 
cell lines were routinely tested for mycoplasma by the Cancer Research UK 
Beatson Institute Molecular Services. For siRNA-mediated knockdown, 5 µl of 
0.5 µmol/L siRNA mix was spotted into wells of 96 well black plates (Greiner 
655090), then 15 µl of Optimem containing 0.15 µl Lipofectamine RNAiMAX 
(Invitrogen: 13778-030) was added and shaken 20-30 min at room temperature. 
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Cells (15,000 in 80 µl DMEM with 10% FBS) were added and incubated for 24 h 
at 37⁰C. 
 
Western blotting 
KPC or TKCC5 cells (5x105) in complete media were plated into the wells of 6-
well culture dishes and allowed to settle and grow overnight. Next day, cells were 
treated with inhibitors or DMSO vehicle in complete media for 1 h. Whole cell 
lysates were prepared with lysis buffer (1% SDS, 50 mM Tris pH 7.5), followed 
by protein concentration determination using the Bicinchoninic assay (Sigma). 
Standard protocols were used for immunoblotting (13). Membranes were 
incubated with primary antibodies: ROCK1 (BD-611136), ROCK2 (BD-610623), 
ROCK1/2 (Millipore 07-1458), total AKT (Cell Signaling 2920S), phospho-AKT 
(Cell Signaling 4060S), phospho-MYPT1 (Millipore 36003), phospho-MLC2 (Cell 
Signaling 3674), total MLC (MRCL3/MRLC2/MYL9; Santa Cruz sc-28329), 
phospho-PRAS40 (Cell Signaling 2997S), total PRAS40 (Cell Signaling 2691S), 
GAPDH (Millipore MAB374) and secondary antibodies: Alexa-Fluor 680 and 
DyLight 800 (Thermo Fisher Scientific)-conjugated antibodies. Infrared imaging 
(Li-Cor Odyssey) was used for detection and quantification of protein signals. 
 
Cell viability assay 
Cell viability was determined using the CellTiter-Glo Luminescent Cell Viability 
Assay (Promega G7570). KPC or TKCC5 cells (2x104) in complete media were 
seeded into the wells of 96-well plates (Greiner 655083) and allowed to settle 
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and grow overnight. Next day, medium was replaced by complete DMEM 
containing inhibitors or DMSO. After 18 h, cell viability was measured according 
to manufacturer’s instructions. 
 
Cell cycle analysis 
KPC cells (5x105) in complete DMEM were plated into the wells of 6-well culture 
dishes and allowed to settle and grow overnight. Cells were treated with 
inhibitors or DMSO vehicle in complete DMEM for 16 h. All cells were harvested 
by centrifugation for 3 min at 720 x g. Cell pellets were re-suspended in 300 µl 
PBS and 400 µl 70% EtOH/H2O added while vortexing. An additional 1.5 ml 70% 
EtOH/H2O was added to cells for fixation at 4°C overnight. Next day, cells were 
centrifuged for 3 min at 720 x g, washed with PBS, and centrifuged again for 3 
min at 720 x g. Finally, cells were incubated with propidium iodide (50 µg/ml, Life 
Technologies P3566) and RNAse A (125 µg/ml, QIAGEN 1007885) in 500 µl 
PBS for at least 30 min prior to analysis by flow cytometry on the Attune Nxt 
Acoustic Focusing Cytometer (Life Technologies). 
 
shRNA lentivirus production 
HEK293 cells (106) were plated in 10 cm dishes and cultured in complete DMEM. 
The following day, medium was replaced with OPTIMEM for 1 h before 
transfections with 3.3 μg pLKO-Non-targeting control, 3.3 μg pLKO-ROCK1 
shRNA (The RNAi Consortium, distributed by Dharmacon; TRCN0000121093) or 
3.3 μg pLKO-ROCK2 shRNA (TRCN0000000978) with 3.3 μg psPAX2 and 3.3 
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μg VSVG plasmids using Fugene HD (Promega) according manufacturer’s 
recommendations. Medium was replaced with complete DMEM 6 h after 
transfection. Supernatants were collected 48 h after transfection, centrifuged at 
1000 rpm for 5 minutes, collected and filtered through 0.45 μm pores. Polybrene 
was added at 8 μg/mL final concentration.  
 
TKCC5 lentiviral transduction  
TKCC5 cells were plated at 2 x 104  per well of a 6 well plate on the same day as 
HEK293 cells were plated for lentivirus production. After 4 days, medium was 
replaced twice in the same day with 4 mL of shRNA lentivirus supernatant. The 
next day, medium was replaced, which was supplemented ~7 h later with 1.25 
µg/mL puromycin. Cells were selected with puromycin for 7 days with regular 
medium changes, then cell numbers were quantified using a CASY cell counter. 
Puromyosin resistant cells  were further cultured in standard TKCC5 medium 
before western blot analysis and Operetta high content imaging analysis. 
 
Immunofluorescence 
KPC cells (6x104) in complete DMEM were seeded onto glass coverslips and 
allowed to settle and grow overnight. Next day, medium was replaced by 
complete DMEM containing inhibitors or DMSO vehicle. After 1 h of drug 
treatment, cells were fixed in 4% paraformaldehyde/PBS for 15 min and 
permeabilized with 0.5% Triton X-100/PBS for 5 min. F-actin was visualized by 
incubation with Alexa Fluor 488 Phalloidin (Thermo Fisher Scientific). Cells were 
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mounted with ProLong Diamond including DAPI (Molecular Probes). Z stack 
images were taken on a Zeiss 710 confocal microscope to generate maximum 
intensity projections using the ZEN 2010 software. 
 
High content imaging 
KPC cells (2x104) in complete DMEM were seeded into the wells of 96-well 
plates (Greiner 655090) and allowed to settle and grow overnight. Next day, 
medium was replaced by complete DMEM containing inhibitors or DMSO vehicle. 
After 1 h of drug treatment, cells were fixed in 4% paraformaldehyde/PBS for 15 
min and permeabilized with 0.5% Triton X-100/PBS for 5 min. Cells were 
consecutively stained with Alexa Fluor 488 Phalloidin (Thermo Fisher Scientific), 
DAPI (0.15 µg/ml), and HCS CellMask Deep Red Stain (Thermo Fisher Scientific 
H32721). The Operetta High Content Imaging System (Perkin Elmer) and the 
Columbus Image Data Storage and Analysis System (Perkin Elmer) were used to 
determine cellular properties. 
 
Metabolomics 
KPC cells (5x105) in complete DMEM were seeded into the wells of 6-well culture 
dishes and allowed to settle and grow overnight. Next day, medium was replaced 
by complete DMEM containing 1 µM AT13148, 10 µM Y27632, 10 µM H1152, or 
DMSO vehicle. After 24 h of drug treatment, medium was removed, cells were 
washed 3 X with cold phosphate buffered saline (PBS), and then 600 µl of 
aqueous extraction solution (50% methanol, 30% acetonitrile) was added. After 
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mixing at 4°C for 5 minutes, the extraction solution was removed to 
microcentrifuge tubes, shaken at 1400 rpm at 4°C for 10 minutes, and then 
centrifuged for 10 min at 16,100 x g, 4°C. Supernatents were transferred to glass 
HPLC vials and stored at -75°C prior to LC-MS. To determine protein 
concentration per well, plates were assayed using a modified Lowry method 
compared against a BSA protein standard curve. Metabolites were extracted and 
relative levels determined as described in (24).  
An Exactive Orbitrap mass spectrometer (Thermo Scientific, Waltham, 
MA, USA) was used together with a Thermo Scientific Accela HPLC system for 
LC-MS Analysis. The HPLC setup consisted of a ZIC-pHILIC column (SeQuant, 
150 x 2.1mm, 5µm, Merck KGaA, Darmstadt, Germany), with a ZIC-pHILIC 
guard column (SeQuant, 20 x 2.1mm) and an initial mobile phase of 20% 20 mM 
ammonium carbonate, pH 9.4, and 80% acetonitrile. Cell and media extracts (5 
µl) were injected and metabolites separated over a 15 minute mobile phase 
gradient, decreasing the acetonitrile content to 20%, at a flow rate of 200 μL/min 
and a column temperature of 45°C (25). The total analysis time was 23 minutes. 
All metabolites were detected across a mass range of 75-1000 m/z using the 
Exactive mass spectrometer at a resolution of 25,000 (at 200 m/z), with 
electrospray (ESI) ionization and polarity switching to enable both positive and 
negative ions to be determined in the same run. Lock masses were used and the 
mass accuracy obtained for all metabolites was below 5 ppm. Data were 
acquired with Thermo Xcalibur software. 
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The peak areas of different metabolites were determined using Thermo 
TraceFinder software where metabolites were identified by the exact mass of the 
singly charged ion and by known retention time on the HPLC column. 
Commercial standards of all metabolites detected had been analyzed previously 
on this LC-MS system with the pHILIC column.  
 
Macropinocytosis assay 
KPC cells in complete DMEM were seeded into the wells of 24-well culture 
dishes containing circular coverslips that had been washed with 95% ethanol, 
and allowed to settle and grow overnight. When the cells reached ~65% 
confluency, media was removed and cells were incubated with serum-free media 
for 2-4 h, then with serum-free media containing 0.1 mg/ml 
Tetramethylrhodamine (TMR)-Dextran and incubated at 37°C for 30 minutes. 
Plates were placed on ice and gently washed 5-7 times with ~2 ml/well cold PBS. 
Cells were fixed with 3.7% (v/v) formaldehyde solution in PBS at room 
temperature for 15 mins, then rinsed 3 times with PBS. Cells were consecutively 
stained with Alexa Fluor 488 Phalloidin (Thermo Fisher Scientific) and then DAPI 
(0.15 µg/ml). Coverslips were affixed to glass slides with DAKO mounting 
medium and stored on a flat surface in the dark overnight prior to imaging using 
an Olympus FV1000 microscope. The macropinocytic index was quantified as 
described in (26). 
 
Collagen matrix invasion assay 
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The collagen matrix invasion assay was performed and analyzed as previously 
described (13). KPC or TKCC5 cells were each allowed to invade for 8 days. The 
area of invading KPC cells was divided by total area, and ratios were used to 
calculate the invasion index, relative to DMSO control. For TKCC5 cells, the 
invasive index was calculated using the following formula: (number of cells inside 
the collagen matrix)/(total number of cells), as described in (17). 
 
Pliable discontinuous substrates for traction force microscopy. 
Pillar fabrication methods were adapted from Ghassemi et al. (27). 
Polydimethylsiloxane (PDMS; Sylgard 184, Dow Corning) was mixed at a 10:1 
elastomer base:curing agent ratio, degassed and placed onto 35 mm glass 
bottom tissue culture dishes (Mattek). Silicon templates with hole structures were 
placed pattern side down onto the PDMS and allowed to cure at 70°C for 12 h, 
giving PDMS with 2 MPa Young’s modulus. Silicon templates were then removed 
from the cured PDMS while immersed in absolute ethanol. The resulting PDMS 
pillar dimensions were 1.8 µm height, 500 nm diameter, 1 µm center-to-center 
distance in a square array, and were calculated to have pillar bending stiffness of 
3.16 nN/µm using the Euler-Bernoulli beam theory. 
PDMS pillar substrates were coated with human fibronectin (R&D 
Systems) at 10 µg/ml final concentration for 1 h at 37°C. KPC cells were seeded 
at 5,000 cells/cm2 in complete DMEM and allowed to attach overnight. Before the 
start of timelapse microscopy and pillar tracking, 1 µM AT13148, 10 µM Y27632 
or DMSO vehicle were added and incubated for 60 minutes. 
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Timelapse light microscopy was performed using an EVOS FL Auto 1 
microscope with an on-stage incubator (ThermoScientific) operating at standard 
cell culture conditions of 37°C and 5% CO2. Single cell images were captured 
every 2 minutes for 2 h using a 100X air objective with 0.95 numerical aperture 
(Olympus). Timecourse stacks of single cells were aligned using the 
MultiStackReg plugin for ImageJ. Using the ImageJ Nano Tracking plugin (28,29) 
subpixel movement of pillars were measured. The displacement of each pillar at 
one timepoint was calculated relative to the position of the same pillar in the 
timepoint immediately preceding it. Cellular traction forces at each timepoint were 
calculated by multiplying displacements with the pillar bending stiffness. 
Individual cell migration velocity and displacement were obtained by tracking 
single cell movement across time using the Manual Tracking plugin for ImageJ. A 
total of 4 independent experiments were performed with 4 cells per experiment 
and at least 10 pillars per cell were measured for each condition. Each data point 
per condition is the average measurement of ≥160 pillars from 16 cells at a single 
timepoint. 
 
Cell motility 
Individual cell motility was observed with the Livecyte label-free imaging system 
(phasefocus). KPC cells (1x105) in complete DMEM were seeded into the wells 
of 6-well plates (MatTek P06G-1.5.20-F) and allowed to settle and grow 
overnight. Wells were coated with 0.3 mg/ml rat tail collagen type I (Corning 
354249) prior to plating of cells. Next day, medium was replaced by complete 
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DMEM containing inhibitors or DMSO vehicle and, after a 30 min delay, cells 
were imaged every 5 min for 10 h, with a 10x objective lens. The image 
processing tool and the automated cell tracking function provided with the cell 
analysis toolbox was used to determine the instantaneous cell velocities. 
 
Scratch wound migration assay 
The IncuCyte Live Cell Analysis System (Essen Bioscience) was used for the 
measurement of cell migration in scratch wound assays. KPC cells (2x104) in 
complete DMEM were seeded into the wells of 96-well ImageLock plates (Essen 
Bioscience) and allowed to settle and grow overnight. Next day, a scratch wound 
was created in cell monolayers using the Woundmaker device (Essen 
Bioscience). Complete DMEM containing inhibitors or DMSO vehicle was added 
to cells and cells were imaged every 2 h for 48 h. 
 
Animal models 
All mouse experiments were approved by the University of Glasgow College of 
Medicine, Veterinary and Life Sciences Research Ethics Committee, and 
performed under a project license granted by the United Kingdom government 
Home Office, in line with the Animals (Scientific Procedures) Act 1986 and 
European Union Directive 2010/63/EU in a dedicated barriered facility. 
Immunodeficient CD-1 nude mice were purchased from Charles River. AT13148 
was dissolved in 10% DMSO, 1% Tween and 89% water for oral administration 
of 40 mg/kg AT13148 on a schedule with three treatments per week. Fasudil was 
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dissolved in water for oral administration and animals were treated daily with a 
fasudil dose of 2 mg/mouse. 250 µl bromodeoxyuridine (BrdU) was injected into 
the peritoneum 2 h before animals were sacrificed. 
To analyze the effect of AT13148 on tumor cell invasion, KPC cells 
(1x106) in 100 µl PBS were injected into the peritoneum of CD-1 females. 
Similarly, KPC (1x106) cells in 100 µl PBS were IP injected into CD-1 males to 
assess the effect of fasudil. Animals were treated with AT13148 or fasudil 
respectively, and body weights were monitored. After 2 weeks, animals were 
sacrificed as per institutional guidelines. 
To analyze the effect of AT13148 on KPC tumor cell growth, KPC cells 
(1x106) in 100 µl PBS were injected subcutaneously into the right flank of CD-1 
females. Animals were treated with AT13148 till endpoint, which was typically 
tumor ulceration. Body weight was monitored over the whole time of the 
experiment. Tumor measurements were taken 3 times weekly, starting 11 days 
after KPC cell injection when tumors had reached about 50-100 mm3 volumes. 
Tumor volumes were calculated using a modified ellipsoid formula: volume = 
(length x width2/2) (30). 
 
Histology 
Tissues were fixed in 10% formalin at room temperature and standard 
histological methods were used for processing and staining. Paraffin-embedded 
sections were rehydrated and immersed in boiling 10 mM citric acid buffer at pH 
6.0 for 20 min. After blocking with H2O2 and normal goat serum, tissues were 
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incubated with primary anti-BrdU antibody (BD Bioscience, 347580), followed by 
incubation with Envision + System-HRP labeled Polymer (Dako), and Liquid DAB 
+ Substrate (Dako). 
The Leica SCN 400f scanner and Leica Slidepath Digital Image Hub 
software were used to image and analyze the tissues. KPC tumor cell invasion 
into the pancreas was determined on H&E stains. Regions that show KPC tumor 
cells in-between the normal pancreatic cells were measured and expressed as 
percentage of the total pancreas area. An algorithm was used to determine 
numbers of BrdU positive nuclei. Images were taken on an Olympus BX51 
microscope. 
 
Statistical analysis 
Statistical significance was determined using one-way ANOVA and post-hoc 
Dunnett’s multiple comparison test, or using two-way ANOVA and post-hoc 
Dunnett’s multiple comparison test as indicated in the figure legends. For 
comparisons between two conditions, either paired or unpaired Student’s t-tests 
were used, or exact p values calculated by Mann Whitney tests as indicated in 
the figure legends. IC50 values were determined by four parameter variable slope 
nonlinear curve fitting. Error bars indicate standard error of the mean (± SEM). *, 
p<0.05; **, p<0.01; ***, p<0.001. 
 
RESULTS 
AT13148 efficiently inhibits ROCK-mediated substrate phosphorylation 
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To determine whether AT13148 inhibited ROCK activity in PDAC cells, 
genetically defined mouse KPC (LSL-KrasG12D; LSL-p53R172H; Pdx1-Cre) tumor 
cells were treated with AT13148 ranging from 10 nM to 10 µM, or the ROCK 
selective inhibitors Y27632 (10 µM) (31) or H1152 (10 µM) (32) for 1 hour. 
Western blotting revealed significantly reduced phosphorylation of the ROCK 
substrate myosin light chain 2 (pMLC2) (33) relative to total MLC2 (tMLC) by 
AT13148 (AT) concentrations ≥ 0.03 µM, or by Y27632 (Y) and H1152 (H) 
compared to DMSO vehicle controls (Figs. 1A and 1B, left panel). Reduced 
phosphorylation was also observed for the ROCK substrate myosin-binding 
subunit of the MLC phosphatase (MYPT1) (34) relative to GAPDH by AT13148 
concentrations ≥ 1 µM, or by Y27632 and H1152 (Figs. 1A and 1B, right panel). 
Expression of ROCK1 and ROCK2 were unaffected by any drug concentration 
(Fig. 1A, Supplemental Figs. S1A and S1B). Curve fitting gave IC50 values for the 
inhibition of MLC2 phosphorylation by AT13148 of 0.026 µM (Fig. 1B, left panel 
inset), and for the inhibition of MYPT1 phosphorylation of 0.069 µM (Fig. 1B, right 
panel inset). 
 Given that AT13148 also inhibits AKT in vitro kinase activity significantly, 
albeit less potently than ROCK1 (IC50 = 6 nM) or ROCK2 (IC50 = 4 nM), with IC50 
values for AKT1 (38 nM), AKT2 (402 nM) and AKT3 (50 nM) (21), KPC cells 
were treated with varying AT13148 concentrations from 10 nM to 10 µM, as well 
as 10 µM Y27632 and 10 µM H1152. Western blotting revealed reduced 
phosphorylation of the AKT substrate PRAS40 (Proline-Rich AKT Substrate) (35) 
relative to total PRAS40 by AT13148 only at 10 µM, with a calculated IC50 = 3.9 
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µM (Figs. 1C and 1D, left panel and inset). It has previously been determined 
that AKT inhibitors can lead to hyperphosphorylation of AKT on regulatory sites 
(including S473), leading to AKT activation that can counteract the effects of 
small molecule inhibitors (36). Western blotting of AT13148 treated cells indeed 
revealed profound AKT S473 phosphorylation (Figs. 1C and 1D, right panel and 
inset), providing an explanation for the relatively low potency of AT13148 as an 
AKT inhibitor in pancreatic cancer cells. Both Y27632 and H1152 did not affect 
PRAS40 or AKT phosphorylation (Figs. 1C and 1D). 
To determine the potency of AT13148 in human pancreatic cancer cells, 
PDX-derived TKCC5 cells were treated with AT13148 ranging from 10 nM to 10 
µM, or the ROCK selective inhibitors Y27632 (10 µM) or H1152 (10 µM) for 1 
hour. Western blotting revealed significantly reduced phosphorylation of the 
ROCK substrate pMLC2 relative to total MLC2 by AT13148 concentrations ≥ 
0.01 µM, or by Y27632 and H1152 compared to DMSO vehicle controls (Figs. 1E 
and 1F, left panel). Reduced phosphorylation was also observed for the ROCK 
substrate MYPT1 relative to GAPDH by AT13148 concentrations ≥ 0.03 µM, or 
by Y27632 and H1152 (Figs. 1E and 1F, right panel). Expression of ROCK1 and 
ROCK2 were unaffected by any drug concentration (Fig. 1E). Curve fitting gave 
IC50 values for the inhibition of MLC2 phosphorylation by AT13148 of 0.005 µM 
(Fig. 1F, left panel inset), and for inhibition of MYPT1 phosphorylation of 0.022 
µM (Fig. 1F, right panel inset), revealing ROCK sensitivity to AT13148 inhibition 
in human tumor cells 3-5 times greater than in mouse PDAC cells. 
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The effects of AT13148 at concentrations from 10 nM to 10 µM, as well as 
10 µM Y27632 and 10 µM H1152, on viable KPC cell numbers were examined 
after 18 hours of treatment. While Y27632 and H1152 were without effect, 
AT13148 reduced viable cell numbers at the highest 10 µM treatment (Fig. 1G), 
which was associated with a reduced proportion of cells in G0/G1 and increased 
proportion in G2/M cell cycle phase (Fig. 1H), consistent with the reported effect 
of complete genetic deletion of Rock1 and Rock2 on cell cycle progression in 
mouse embryonic fibroblasts (10). Comparable effects of AT13148 on viability 
were also observed for human TKCC5 PDAC cells (Fig. 1I). Consistent with the 
reported inhibition of proliferation of pancreatic cancer cell lines in vitro following 
siRNA-mediated knockdown of ROCK1/2 (12) and supporting the effect of 
AT13148 on proliferation being the result of ROCK inhibition, shRNA-mediated 
ROCK1/2 knockdown (Supplemental Figure S2A) significantly reduced TKCC5 
cell numbers (Fig. 1J). Subsequent experiments used non-toxic AT13148 
concentrations up to 3 µM. These results indicate that AT13148 is a potent 
ROCK inhibitor, but ineffective AKT inhibitor due to compensatory mechanisms, 
in mouse and human PDAC cells.  
 
AT13148 effects on cell morphology  
Given the central and critical role of ROCK kinases in actomyosin cytoskeleton 
and cell morphology regulation (7), the effects on KPC cells of a range of 
AT13148 concentrations were compared to the ROCK selective inhibitors 
Y27632 and H1152, or to shRNA-mediated knockdown of ROCK1 and ROCK2 in 
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TKCC5 cells (Supplementary Fig. S2A) or siRNA-mediated knockdown of Rock1 
and Rock2 in KPC cells (Supplemental Fig. S2B). Cells were fixed and stained 
with fluorescent phalloidin to visualize filamentous actin (F-actin) structures one 
hour after drug treatment (Fig. 2A). High content analysis (HCA) revealed dose 
dependent increases in total cell area (Fig. 2B and Supplemental Fig. S2C; IC50 
= 0.18 µM), and cell length (Fig. 2C and Supplemental Fig. S2D; IC50 = 0.19 µM) 
induced by AT13148 that were significant at doses ≥ 0.3 µM, and for 10 µM 
Y27632 and H1152. Accompanying the increased cell area and length, the 
width/length ratios were significantly decreased at AT13148 concentrations ≥ 0.1 
µM, and for 10 µM Y27632 and H1152 (Fig. 2D and Supplemental Fig. S2E; IC50 
= 0.16 µM), while overall cell roundness also significantly decreased at AT13148 
concentrations ≥ 0.01 µM, and for 10 µM Y27632 and H1152 (Fig. 2E and 
Supplemental Fig. S2F; IC50 = 0.33 µM). Consistent with the effect of the small 
molecular inhibitors being the result of ROCK inhibition, siRNA-mediated Rock1 
and Rock2 knockdown in KPC cells, or shRNA-mediated ROCK1 and ROCK2 
knockdown in TKCC5 cells, induced significant changes in each morphological 
parameter relative to non-targeting control (NTC) cells, in the same direction as 
AT13148, Y27632 or H1152 treatment (Figs. 2B-E). Using multiparametric 
analysis and applying a machine-learning algorithm (37) to classify cells either 
into “regular” or “irregular” morphologies, it was determined that AT13148 
significantly shifted the distribution of cell morphologies from regular towards 
irregular at concentrations ≥ 0.1 µM, as did 10 µM Y27632, 10 µM H1152, or 
siRNA-mediated Rock1 and Rock2 knockdown in KPC cells or shRNA-mediated 
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ROCK1 and ROCK2 knockdown in TKCC5 cells (Fig. 2F, Supplemental Figs. 
S2G and S2H; IC50 = 0.18 µM). In addition, there were subtle but significant 
effects on nuclear morphology in KPC cells induced by AT13148, Y27632 and 
H1152 treatments (Supplemental Figs. S3A and S3B). Taken together, these 
observations reveal potent effects of AT13148 on cell morphology that 
phenocopy the actions of the ROCK selective inhibitors Y27632 and H1152, or 
the effect of ROCK knockdown induced by siRNA or shRNA. 
 
Effect of ROCK inhibitors on tumor cell metabolism 
To characterize the metabolic alterations induced by 1 µM AT1318, 10 µM 
Y27632 or 10 µM H1152 treatment, KPC cell extracts were prepared and 
metabolites analyzed as described in Tardito et al. (24). Results in Figure 3A are 
plotted at the negative or positive percentage change relative to DMSO vehicle 
treatment (100%), and two-way ANOVA and post-hoc Dunnett’s multiple 
comparison tests were used to identify significant effects relative to DMSO 
treatment. Given that the concentrations of these three inhibitors potently 
inhibited ROCK substrate phosphorylation, and that there were no significant 
effects in the same direction induced by all three inhibitors, ROCK activity likely 
does not play a major role in regulating metabolism in PDAC cells. There were 
some significant responses to 1 µM AT13148, including decreased lactate, 
succinic acid and pyruvate, which suggest that this compound may have ROCK 
and AKT independent effects on metabolism. Interestingly, H1152 and Y27632 
significantly increased phosphoenolpyruvate (PEP) levels, while AT13148 
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significantly decreased PEP (Fig. 3A). In addition, both H1152 and Y27632 
significantly decreased AMP and ADP levels, which were unaffected by 
AT13148. Taken together, these results are consistent with all three small 
molecules having spectra of off-target effects on metabolic pathways, which have 
not previously been considered either as part of their apparent mechanisms of 
action, or as potential therapeutic liabilities. 
PDAC cells have also been shown to obtain nutrients via scavenging of 
extracellular proteins acquired through macropinocytosis (38,39). When KPC 
cells were treated with 1 µM AT1318, macropinocytic activity measured by 
tetramethylrhodamine (TMR) dextran uptake was significantly inhibited (Fig. 3B). 
Therefore, under conditions of nutrient deprivation, AT13148 would be expected 
to limit access to this alternative source. 
 
PDAC invasion is inhibited by AT13148 
Pancreatic tumor masses have significant collagen content that cells move 
through to enable primary tumor growth, invade local tissue and to metastasize. 
A 3-dimensional (3D) collagen matrix invasion assay, in which cells invade 
through fibroblast-remodeled collagen matrix towards serum-containing medium, 
was used previously to demonstrate ROCK dependence of PDAC invasive 
behavior (13,40). Invasion of KPC mouse PDAC cells was significantly inhibited 
by AT13148 at concentrations ≥ 0.3 µM and by 10 µM Y27632 (Fig. 4A). In 
addition, invasion was significantly inhibited by the broad specificity matrix 
metalloproteinase inhibitor GM6001 (10 µM) (41). Consistent with these 
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observations, treatment of human PDX-derived TKCC5 tumor cells with 1 µM 
AT13148 significantly inhibited 3D collagen invasion (Fig. 4B). Interestingly, the 
inhibition of invasion resulting from GM6001 was less than the inhibition induced 
by 1 µM or 3 µM AT13148, or by 10 µM Y27632, suggesting that ROCK activity 
was required for an activity additional to promoting collagen degradation, or an 
activity more important than MMP activity for invasion, such as cell motility.  
 
Cell migration and contractile force generation 
A possible explanation for the significant effect of ROCK inhibition on collagen 
invasion was decreased cell motility. To determine whether ROCK activity was 
required for migration across two-dimensional (2D) surfaces, confluent KPC 
monolayers were scratched and the migration of cells to close the wound was 
monitored in real time over 48 hours. Concentrations of AT13148 from 0.01 µM 
to 3 µM, as well as 10 µM Y27632 or 10 µM H1152, did not significantly affect 
wound closure over all time points or at 24 hours when wound closure was ~50% 
(Fig. 5A). Furthermore, instantaneous random cell migration velocities were not 
affected when KPC cells were monitored for 10 hours in the presence of 
AT13148 from 0.3 µM to 3 µM, 10 µM Y27632 or 10 µM H1152 (Fig. 5B). These 
results indicate that migration across planar stiff surfaces, akin to “mesenchymal” 
migration that is largely dependent on actin polymerization to push cells forward, 
was not sensitive to ROCK inhibition (42). 
 To determine whether ROCK inhibition by AT13148 or Y27632 would 
affect forces applied to the substrate on which cells were attached, KPC cells 
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were plated on grids of flexible nanopillars (27) and pillar deflection distances 
collected over 2 hours was used to calculate absolute forces exerted (Fig. 5C). 
Consistent with the role of ROCK in the generation of actomyosin contractile 
force, treatment with 1 µM AT13148 or 10 µM Y27632 significantly decreased the 
force exerted on nanopillars (Fig. 5D). The imaging of single cells on nanopillars 
was also used to determine cell velocity; 1 µM AT13148 or 10 µM Y27632 
significantly decreased cell movement on the flexible substrate (Fig. 5E). Unlike 
migration on planar stiff surfaces, movement on flexible discontinuous substrates 
apparently does require contractile force, consistent with previous studies that 
modelled migration modes on varying substrate geometries (43). 
 
In vivo inhibition of PDAC invasion and tumor growth by AT13148 
Although the 3D collagen invasion assay recapitulates aspects of the in vivo 
environment, only an in vivo model would resemble the complex environments 
encountered by invasive tumor cells. KPC cells (106) were injected into the 
peritoneal cavity of CD-1 immunocompromised mice, which were then treated for 
2 weeks with 40 mg/kg AT13148 three times per week, daily treatment with 2 
mg/mouse (~80 mg/kg) of the ROCK selective inhibitor fasudil, or corresponding 
vehicle solutions with matched volumes. Over the 2 weeks, there were no 
significant effects of either compound on mouse weights (Supplemental Figs. 
S4A and S4B), indicating that both were well tolerated. Histopathology revealed 
that tumor cells had homed to the pancreas, where they grew onto and invaded 
into healthy tissue (Fig. 6A upper panels; note the pale tumor cells mixed with 
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darker healthy pancreas). In contrast, in AT13148 treated mice, tumor cells 
homed and grew on the pancreas, but a clearly demarcated border was 
consistently observed between tumor and normal tissue (Fig. 6A lower panels). 
When the area of the invasive region, in which tumor cells were intermixed with 
normal pancreas cells, was expressed as a percentage of the total pancreas for 
each condition, there was a significant decrease in the invasive region for 
AT13148 treated mice (Fig. 6A), which approached significance for the less 
potent ROCK inhibitor fasudil treated mice (Fig. 6B). To determine whether the 
anti-invasive effect of AT13148 treatment was due to decreased proliferation, 
mice were injected with bromodeoxyuridine (BrdU) 2 h before sacrifice, and then 
tissues were stained with anti-BrdU antibody (Fig. 6C). Counting the percentage 
of BrdU positive tumor cells indicated that there was no effect of AT13148 on 
proliferation (Fig. 6D), indicating that reduced invasion of pancreatic tissue was a 
direct effect on invasive behaviors. 
AT13148 was previously reported to reduce the growth of subcutaneous 
xenograft tumors of BT474 breast, PC3 prostate and MES-SA uterine cancer cell 
lines (21). However, the mechanism of tumor growth inhibition was not 
determined, and proliferation was not directly examined. Given that it has been 
proposed that even short range cell dispersal leads to faster tumor growth (44), 
we wished to determine whether PDAC xenograft tumor growth would be 
affected by the anti-invasion effect of AT13148. KPC cells (106) in 100 µl PBS 
were injected subcutaneously into the right flank of CD-1 mice, and were treated 
with 40 mg/kg AT13148 or vehicle control until endpoint, which was typically 
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tumor ulceration. Body weights again showed no difference induced by AT13148 
treatment (Supplemental Fig. S4C). Tumor measurements were taken 3 times 
weekly, starting 11 days after KPC cell injection when tumors had reached 50-
100 mm3 volumes (Supplemental Figs. S5A and S5B). Pairwise comparisons 
revealed significantly reduced tumor growth at each day between days 18 to 25 
(Fig. 6E). As before, mice were treated with BrdU 2 hours prior to sacrifice and 
BrdU positive cells quantified for each condition. As before, AT13148 did not 
significantly affect proliferation as indicated by no difference in BrdU positivity 
between conditions (Fig. 6F), consistent with the anti-invasive actions of 
AT13148 being responsible for reducing tumor growth, rather than an anti-
proliferative effect. 
 
DISCUSSION 
The lack of effective therapies for pancreatic cancer has led to considerable 
effort being directed at discovering new therapeutic strategies (6). Difficulties with 
drugging the major oncogenic drivers mean that alternative approaches are 
required. We found that the potent inhibitor AT13148 has anti-tumor properties 
that support its development for PDAC treatment as part of a chemotherapeutic 
combination or in an adjuvant setting. 
 Originally discovered on the basis of being an AKT inhibitor, it was 
subsequently determined that AT13148 is a multi-AGC kinase inhibitor with 
significant potency for ROCK1 and ROCK2 (21). We found that AT13148 
induced comparable, if not greater, effects compared to the selective ROCK 
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inhibitors Y27632 and H1152 on substrate phosphorylation (Fig. 1), cell 
morphology (Fig. 2), migration on discontinuous pliable substrates (Fig. 5) and 
invasion into three-dimensional collagen matrix (Fig. 4) in mouse and human 
PDAC cells, consistent with ROCK inhibition being a key mechanism of action. 
Interestingly, AT13148 was determined to be a relatively poor AKT inhibitor (Figs. 
1C and 1D), likely due a previously described compensatory mechanism that 
leads to AKT phosphorylation on the activating S473 site (36). We also 
determined that AT13148 significantly reduced macropinocytosis (Fig. 3B), which 
allows mutant KRAS expressing PDAC cells to obtain nutrients via scavenging of 
extracellular proteins. Previous studies revealed that Kaposi's Sarcoma-
Associated Herpesvirus entry via macropinocytosis was sensitive to ROCK 
inhibition (45), consistent with ROCK on-target actions of AT13148 being 
responsible for the reduction in macropinocytic activity.  
 Invasion of three dimensional collagen matrices by KPC mouse PDAC 
tumor cells was previously found to be sensitive to Y27632 (40), which we 
confirmed and extended by showing dose-dependent inhibition by AT13148 (Fig. 
4A). In addition, collagen invasion by the human PDX-derived TKCC5 PDAC cell 
line was significantly inhibited by AT13148 (Fig. 4B). Interestingly, collagen 
invasion was more sensitive to ROCK inhibition by Y27632 or AT13148 than to 
the general MMP inhibitor GM6001, suggesting that ROCK activity was required 
for an activity in addition to MMP-mediated collagen degradation, or that ROCK 
contributed to a function that was more important for collagen invasion than 
matrix degradation (Fig. 4A). Given that invasion is dependent on the ability of 
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cells to move, we examined motility on stiff planar surfaces as well as on 
discontinuous pliable substrates. Interestingly, ROCK inhibition did not affect 
migration on two dimensional surfaces as determined for monolayer wound 
healing (Fig. 5A) or individual random cell migration (Fig. 5B). However, 
movement on pliable surfaces was affected by AT13148 and Y27632 (Fig. 5E), 
which was paralleled by significantly reduced force being exerted on underlying 
substrates (Fig. 5D). These results reveal different requirements for ROCK 
activity and contractile force for movement on varying surfaces, suggesting that 
ROCK activity was dispensable for “mesenchymal” migration on stiff planar 
substrates, but necessary for migration on discontinuous and pliable surfaces 
that more closely reflect the in vivo environment.  
  When KPC mouse PDAC cells were injected into the peritoneal cavity of 
CD-1 immunocompromised mice, a proportion of cells homed to the pancreas 
where they formed tumors and invaded healthy tissue (Fig. 6A). By treating mice 
with AT13148, invasion into pancreatic tissue was effectively inhibited, resulting 
in clear separation between tumor and pancreas (Fig. 6A), an observation largely 
replicated in fasudil treated mice (Fig. 6B). Interestingly, BrdU labelling of tumor 
cells was not different between control and AT13148 treated mice (Fig. 6D), 
indicating that the anti-invasive effect was independent of anti-proliferative 
effects. Although we did observe inhibition of cell cycle progression at the highest 
10 µM AT13148 concentration in vitro, which was consistent with the cell cycle 
arrest induced by Rock1/Rock2 deletion in mouse cells (10), it seems likely that 
the concentrations attained in pancreatic tissue in vivo were below levels that 
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would result in attenuated proliferation. When tumor cells were injected 
subcutaneously, AT13148 significantly slowed increases in tumor volume (Fig. 
6E and Supplemental Fig. S5), which also was not associated with differences in 
BrdU labelling of tumor cells (Fig. 6F). These results are consistent with the 
effect of AT13148 on tumor growth is not due to inhibition of proliferation, but is 
more likely a reflection of reduced movement of cells within the tumor mass and 
invasion of local adjacent tissue. It was recently proposed that even short range 
cell dispersal leads to faster tumor growth (44), which suggests that inhibition of 
invasion and cell motility would have broad positive consequences on slowing 
primary tumor growth, in addition to the potential benefits from reducing the 
invasion of local healthy tissue (Fig. 6A) and from inhibiting distant metastasis 
(22). 
 The results from this study support the potential for further development of 
AT13148 for pancreatic cancer therapy. Its clinical value would arise from its 
ability to restrict tumor cell invasion, which would slow tumor growth and possibly 
enable surgical resection by helping to maintain separation between tumor and 
healthy tissue. In addition to patients with amplified or elevated ROCK 
expression (13), activation of ROCK activity by stiff desmoplastic stroma (18,46) 
suggests that a broad range of patients would likely benefit from ROCK inhibitor 
treatment. A recent study found that treatment of mice bearing PDX-derived 
xenograft PDAC tumors with fasudil increased therapeutic responses to 
gemcitabine and nab-paclitaxel, increased the sensitivity of tumor cells to shear 
stress, and decreased metastasis to the liver (17). It was proposed that transient 
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ROCK inhibition with fasudil affected the tumor-associated extracellular matrix 
and vasculature, thus “priming” tumors to be more responsive to standard 
chemotherapies. Consistent with these conclusions, the use of AT13148 would 
likely be restricted to combination therapy or in an adjuvant setting, given that its 
actions as a single agent significantly slowed tumor growth, but have not been 
seen to result in overt tumor regression in this or prior in vivo studies (21,47).  
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FIGURE LEGENDS 
Figure 1. Potent inhibition of substrate phosphorylation by AT13148. 
A, KPC mouse PDAC cells were treated with DMSO vehicle or indicated 
concentrations of AT13148, Y27632 or H1152 for 1 hour, then immunoblotted for 
ROCK1, ROCK2, phosphorylation of MLC2 (pMLC2; T18S19), total MLC (tMLC), 
phosphorylation of MYPT (pMYPT1; T850) and GAPDH B, Left panel 
Quantifications represent the ratio of pMLC2 to total MLC as percentage relative 
to DMSO vehicle. Means ± SEM are shown from n = 3 independent experiments. 
Statistical significance was determined using one-way ANOVA and post-hoc 
Dunnett’s multiple comparison test. ***, p<0.001. Inset Four parameter variable 
slope non-linear curve fitting of pMLC2/total MLC percentages was used to 
determine IC50 value. Right panel Relative pMYPT1 to GAPDH signal as 
percentage of DMSO vehicle. Means ± SEM are shown from n = 3 independent 
experiments. Statistical significance was determined using one-way ANOVA and 
post-hoc Dunnett’s multiple comparison test. *, p<0.05. Inset Four parameter 
variable slope non-linear curve fitting of pMPYT1/GAPDH percentages was used 
to determine IC50 value. C, KPC cells were treated with DMSO or indicated 
concentrations of AT13148, Y27632 or H1152 for 1 hour, then immunoblotted for 
phosphorylation of PRAS40 (pPRAS40; T246), total PRAS40, phosphorylation of 
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AKT (pAKT; S473), or total AKT. D, Left panel Ratio of pPRAS40 to PRAS40 as 
percentage of DMSO vehicle. Means ± SEM are shown from n = 3 independent 
experiments. Inset Four parameter variable slope non-linear curve fitting of 
pRAS40/PRAS percentages was used to determine IC50 value. Right panel Ratio 
of pAKT to AKT as percentage of DMSO vehicle. Means ± SEM are shown from 
n = 3 independent experiments. Inset Four parameter variable slope non-linear 
curve fitting of pAKT/AKT percentages was used to determine IC50 value. E, 
TKCC5 human PDAC cells were treated with DMSO vehicle or indicated 
concentrations of AT13148, Y27632 or H1152 for 1 hour, then immunoblotted for 
ROCK1, ROCK2, pMLC2, total MLC, pMYPT1, and GAPDH. F, Left panel Ratio 
of pMLC2 to total MLC as percentage of DMSO vehicle. Means ± SEM are 
shown from n = 3 independent experiments. Statistical significance was 
determined using one-way ANOVA and post-hoc Dunnett’s multiple comparison 
test. ***, p<0.001. Inset Four parameter variable slope non-linear curve fitting of 
pMLC2/total MLC percentages was used to determine IC50 value. Right panel 
Relative pMYPT1 to GAPDH signal as percentage of DMSO vehicle. Means ± 
SEM are shown from n = 3 independent experiments. Statistical significance was 
determined using one-way ANOVA and post-hoc Dunnett’s multiple comparison 
test. *, p<0.05. **, p<0.01. ***, p<0.001. Inset Four parameter variable slope non-
linear curve fitting of pMPYT1/GAPDH percentages was used to determine IC50 
value. G, Effects of AT13148, Y27632 or H1152 on KPC cell viability after 18 h 
drug treatment. Means ± SEM are shown from n = 4 independent experiments. 
H, Cell cycle analysis of KPC cells treated with a concentration range of 
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AT13148 for 16 h. Means ± SEM are shown from n = 3 independent 
experiments. I, Effects of AT13148, Y27632 or H1152 on TKCC5 cell viability 
after 18 h drug treatment. Means ± SEM are shown from n = 3 independent 
experiments. J, Relative TKCC5 cell numbers 7 days after transduction with non-
targeting control (NTC) or combined ROCK1/2 shRNA lentivirus.  Means ± SEM 
are shown from n = 3 independent experiments. Statistical significance was 
determined for the comparisons of NTC with ROCK1/2 knockdown by unpaired 
Student’s t-test.  **, p<0.01. 
 
Figure 2. AT13148 affects cell morphology. 
A, Representative confocal microscope maximum intensity projection images of 
F-actin (green) and DAPI (blue) stained KPC cells treated with indicated 
concentrations of AT13148, Y27632 or H1152 for 1 h. Alternatively, cells were 
transfected with non-targeting control (NTC) or a mixture of Rock1 + Rock2 
(Rock1/2) siRNAs and imaged on an Operetta High Content Imaging System. 
High content imaging of KPC cells after 1 h of AT13148, Y27632 or H1152 drug 
treatment, or 24 h post siRNA transfection (left graphs), or >7 days post lentiviral 
transduction of TKCC5 cells with NTC or ROCK1 and ROCK2 targeted shRNAs 
(right graphs), was used to determine B, cell area; C, cell length; D, cell 
width/length ratios; E, cell roundness. Means ± SEM are shown from n = 3 
independent experiments for drug treatments, n = 4 independent experiments for 
siRNA transfections, or n = 3 independent experiments with shRNA knockdown 
cells. Statistical significance was determined using one-way ANOVA and post-
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hoc Dunnett’s multiple comparison test for AT13148, Y276732 or H1152 
treatments. Statistical significance was determined for the comparisons of 
corresponding NTC with Rock1/2 or ROCK1/2 knockdown by unpaired Student’s 
t-test.  *, p<0.05; **, p<0.01; ***, p<0.001. F, Multiparametric analysis was used 
to classify cells as irregular (white bar) or regular (hatched bar), as typified by the 
indicated cells. Means ± SEM are shown from n = 3 independent experiments, n 
= 4 independent experiments for siRNA transfections, or n = 3 independent 
experiments with shRNA knockdown cells. Statistical significance was 
determined using one-way ANOVA and post-hoc Dunnett’s multiple comparison 
test for AT13148, Y276732 or H1152 treatments. Statistical significance was 
determined for the comparisons of corresponding NTC with Rock1/2 or ROCK1/2 
knockdown by unpaired Student’s t-test.  **, p<0.01; ***, p<0.001. 
 
Figure 3. Effect of ROCK inhibitors on PDAC cell metabolism. 
A, Normalized levels of intracellular metabolites in cells treated with 1 µM 
AT13148, 10 µM H1152 or 10 µM Y27632 for 24 hours as negative or positive 
relative differences from DMSO treated controls. Means ± SEM are shown from n 
= 4 independent experiments. Colored * indicates p<0.05 for corresponding drug 
treatment using two-way ANOVA and post-hoc Dunnett’s multiple comparison 
test compared to DMSO. B, Macropinocytic index was measured as described in 
(26) by examining the uptake of tetramethylrhodamine (TMR)-Dextran over 30 
minutes by confocal microsopy. Means ± SEM are shown for 80 DMSO and 80 
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AT13148 treated cells. Statistical significance was determined by unpaired 
Student’s t-test. ***, p<0.001. 
 
Figure 4. Collagen matrix invasion is efficiently inhibited by AT13148. 
A, H&E-stained sections of KPC cell invasion into fibroblast-conditioned collagen 
matrix after 8 days, which included treatment with AT13148, Y27632 or GM6001 
as indicated. The invasion index was normalized to DMSO control conditions, 
with means ± SEM shown from n = 3 independent experiments. Statistical 
significance was determined using one-way ANOVA and post-hoc Dunnett’s 
multiple comparison test. *, p<0.05; **, p<0.01; ***, p<0.001. B, H&E-stained 
sections of TKCC5 cell invasion into fibroblast-conditioned collagen matrix after 8 
days, which included treatment with AT13148. The invasion index was 
normalized to DMSO control conditions, with means ± SEM shown from n = 3 
independent experiments. Statistical significance was determined using unpaired 
Student’s t-test. ***, p<0.001. 
 
Figure 5. AT13148 reduces physical force and migration on pliable 
substrates. 
A, Directed scratch wound migration of AT13148, Y27632 or H1152 drug-treated 
cells was monitored over 48 hours. Left: Representative images at 0 and 24 
hours for DMSO and 1 µm AT13148 treated cells. Upper right graph shows mean 
± SEM percentage wound confluence acquired every 2 hours over 48 hours for 
n=6 replicates. Lower right graph shows mean ± SEM percentage wound 
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confluence at 24 hours for n=3 independent experiments. B, Random migration 
of cells treated with AT13148, Y27632 or H1152 was monitored over 10 hours. 
Left panels show representative images at 0, 5 and 10 hours. Means ± SEM are 
shown from n = 3 independent experiments. C, Schematic diagram and 
representative images of cells on nanopillars with DMSO, AT13148 or Y27632 
treatments as indicated. D, Forces leading to nanopillar deflection were 
determined for ≥10 pillars under 16 cells for AT13148 and Y27632 treatments, 
and for 32 cells for DMSO. Mean force values determined at each 2 minute 
interval over 120 minutes are plotted for each condition, with indicated means ± 
SEM. Statistical significance was determined using one-way ANOVA and post-
hoc Dunnett’s multiple comparison test. ***, p<0.001. E, Velocities of 16 cells for 
AT13148 and Y27632 treatments, and of 32 cells for DMSO were determined 
from time lapse images acquired every 2 minutes over 2 hours. Mean velocities 
determined at each 2 minute interval over 120 minutes are plotted for each 
condition, with indicated means ± SEM. Statistical significance was determined 
using one-way ANOVA and post-hoc Dunnett’s multiple comparison test. ***, 
p<0.001. 
 
Figure 6. AT13148 blocks PDAC invasion and tumor growth in vivo. 
A, Mouse PDAC cells were injected into the peritoneum of CD-1 mice and 
animals were treated with vehicle or AT13148 (40 mg/kg, 3 x per week) for 14 
days. Left: Representative H&E-stained sections of pancreas (dark staining) and 
invading tumor cells (light staining). Right: Quantification of pancreas area 
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invaded by KPC tumor cells. Means ± SEM are shown for n=7 for vehicle-treated 
and n=8 for AT13148-treated mice. Exact P value by Mann-Whitney test. B, 
Quantification of pancreas area invaded by KPC tumor cells. Means ± SEM are 
shown for n=8 for vehicle-treated and n=8 for mice treated daily with 2 mg/mouse 
fasudil. Exact P value by Mann-Whitney test. C, Representative image of BrdU 
staining of normal pancreas and tumor cells, with white line indicating normal 
pancreas from region with tumor cells. D, Quantification of percentage BrdU 
staining in KPC tumor cells. Means ± SEM shown for n=8 for vehicle-treated and 
n=8 for AT13148-treated mice. Exact P value by Mann-Whitney test. E, Volumes 
of subcutaneous KPC cell tumors in CD-1 mice treated with AT13148 (40 mg/kg, 
3 x per week) or vehicle control for up to 25 days (dots represent individual 
mice). Statistical significance was determined for vehicle versus AT13148 for 
each day by unpaired Student’s t-test. *, p<0.05. F, Quantification of percentage 
BrdU staining in KPC tumor cells. Means ± SEM shown for n=8 for vehicle-
treated and n=6 for AT13148-treated mice. Exact P value by Mann-Whitney test. 
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